Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C

Hepatology

Volumn 52, Issue 6, 2010, Pages 1906-1914

  Chung, Raymond T ^a   Poordad, Fred F ^b   Hassanein, Tarek ^c   Zhou, Xiaolei ^d   Lentz, Ellen ^e   Prabhakar, Avinash ^e   Di Bisceglie, Adrian M ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RTI HEALTH SOLUTIONS   (United States)

^e GENENTECH INC   (United States)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EXPOSURE; ETHNICITY; FEMALE; GENOTYPE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; POST HOC ANALYSIS; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; BODY WEIGHT; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 78649623875     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23947     Document Type: Article

References (29)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
2. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
4. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
5. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641.
6. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477.
7. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. HEPATOLOGY 2004; 39: 1702-1708.
8. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360: 257-267.
9. Sulkowski M, Vierling JM, Brown K, Flamm Sl, Kwo P, Mullen KD, et al. Probability of sustained virologic response (SVR) is associated with the magnitude of HCV RNA reduction at week 4 of treatment with peginterferon (Peg) plus ribavirin (RBV): results of the IDEAL trial [Abstract 1868]. HEPATOLOGY 2008; 48 (4 Suppl.): 1144A-1145A.
10. Fried MW. Side effects of therapy of hepatitis C and their management. HEPATOLOGY 2002; 36: S237-S244.
11. Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005; 39: S3-S8.
12. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-α. Gastroenterology 2002; 123: 141-151.
13. Seyam MS, Freshwater DA, O'Donnell K, Mutimer DJ. Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C. J Viral Hepat 2005; 12: 531-535.
14. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, et al. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6: 234-241.
15. Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 2010; 17: 139-147.
16. Sulkowski M, Shiffman M, Afdhal N, Reddy R, McCone J, Lee W, et al. Hemoglobin decline is associated with SVR among HCV genotype-1 infected persons treated with peginterferon (Peg)/ribavirin (RBV): analysis from the IDEAL study. J Hepatol 2009; 50: S51-S52.
17. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004; 71( Suppl. 3): S17-S21.
18. McHutchison JG, Manns MP, Brown RS Jr, Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102: 880-889.
19. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124-129.
20. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-112.
21. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.
22. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271.
23. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol 2008; 103: 1981-1988.
24. Jacobson IM, Brown RS Jr, McCone J, Black M, Albert C, Dragutsky MS, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. HEPATOLOGY 2007; 46: 982-990.
25. Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. HEPATOLOGY 2010; 51: 388-397.
26. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
27. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408.
28. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
29. Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; doi:10.1053/j.gastro.2010.06.016.